Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Results available

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

ClinicalTrials.gov ID: NCT02515669

Public ClinicalTrials.gov record NCT02515669. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.

Study identification

NCT ID
NCT02515669
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
43 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
5 Years to 10 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1, 2015
Primary completion
Feb 7, 2018
Completion
Apr 14, 2020
Last update posted
Nov 3, 2020

2015 – 2020

United States locations

U.S. sites
10
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
David Geffen School of Medicine at UCLA Los Angeles California 90095-6984
Stanford University Palo Alto California 94305
University of Florida Gainesville Florida 32607
Nemours Children's Hospital Orlando Florida 32827
Children's Healthcare of Atlanta Atlanta Georgia 30324
Rush University Medical Center Chicago Illinois 60612
University of Kansas Medical Center Kansas City Kansas 66160
Kennedy Krieger Institute Baltimore Maryland 21205
Saint Louis Children's Hospital St Louis Missouri 63110
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02515669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02515669 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →